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This is the first study describing drug resistance mutations (DRM) and HIV-1 variants
among infected pregnant women in Equatorial Guinea (GQ), a country with high (6.2%)
and increasing HIV prevalence.
Methods
Dried blood spots (DBS) were collected from November 2012 to December 2013 from 69
HIV-1 infected women participating in a prevention of mother-to-child transmission program
in the Hospital Regional of Bata and Primary Health Care Centre Marı́a Rafols, Bata, GQ.
The transmitted (TDR) or acquired (ADR) antiretroviral drug resistance mutations at partial
pol sequence among naive or antiretroviral therapy (ART)-exposed women were defined
following WHO or IAS USA 2015 lists, respectively. HIV-1 variants were identified by phylo-
genetic analyses.
Results
A total of 38 of 69 HIV-1 specimens were successfully amplified and sequenced. Thirty
(79%) belonged to ART-experienced women: 15 exposed to nucleoside reverse transcrip-
tase inhibitors (NRTI) monotherapy, and 15 to combined ART (cART) as first regimen
including two NRTI and one non-NRTI (NNRTI) or one protease inhibitor (PI). The TDR rate
was only found for PI (3.4%). The ADR rate was 37.5% for NNRTI, 8.7% for NRTI and
absent for PI or NRTI+NNRTI. HIV-1 group M non-B variants caused most (97.4%) infec-
tions, mainly (78.9%) recombinants: CRF02_AG (55.2%), CRF22_A101 (10.5%), subtype
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C (10.5%), unique recombinants (5.3%), and A3, D, F2, G, CRF06_cpx and CRF11_cpx
(2.6% each).
Conclusions
The high rate of ADR to retrotranscriptase inhibitors (mainly to NNRTIs) observed among
pretreated pregnant women reinforces the importance of systematic DRM monitoring in
GQ to reduce HIV-1 resistance transmission and to optimize first and second-line ART regi-
mens when DRM are present.
Introduction
Equatorial Guinea (GQ) is a small country located in West Central Africa betweenCameroon
and Gabon. HIV/AIDS is still a major cause of mortality and morbidity in GQ, and the most
common routes of HIV transmission are heterosexual, followed by vertical transmission from
mother to child and transfusions [1]. HIV prevalence is high (6.2%) and in 2015 more than
half of the 27,000 people living with HIV in the country were women aged 15 onwards (http://
www.unaids.org/en/regionscountries/countries/equatorialguinea). In the last decade, HIV
prevalence has increased in the Equatoguinean population of 15 to 49 years of age (3.2% in
2004 and 6.2% in 2014 and in pregnant women (1.5% in 1997 and 10.1% in 2013) [1].
The use of antiretroviral therapy (ART) started on a regular basis in 2005 in GQ, although
sporadic treatments, interrupted exposure to drugs, and high rates of loss to follow-up could
have caused the appearance of resistance mutations, affecting the success of a future systematic
antiretroviral program if the drug families causing resistance were still given to women carry-
ing resistant viruses. The use of antiretroviral (ARV) regimens with a high genetic barrier to
resistance, including new drug families, combined with improved patient adherence may miti-
gate acquired antiretroviral drug resistance mutations (ADR) rates, reducing the generation of
new ARV-resistant strains. However, their higher prices are problematic for their wide use in
poor countries with high HIV prevalence.
After confirmation of positive HIV diagnosis using 3 rapid tests according to GQ’s National
Protocol [2], combined ART (cART) including zidovudine (AZT) + lamivudine (3TC) + nevi-
rapine (NVP) are given to pregnant women with World Health Organization (WHO) clinical
stage 3 or 4, or CD4 under 350 cell/mm3 as recommended by the National Plan to Combat
HIV/AIDS in GQ. However those with WHO clinical stage 1 or 2, or CD4 above 350 cells/
mm3 receive prophylaxis with AZT from the 28th week of gestation, with AZT, 3TC and NVP
at the time of delivery, followed by AZT and 3TC for one week postpartum to avoid the selec-
tion of resistance to single dose NVP. The protocol recommends that, after birth, the child
receives a single dose of NVP and prophylaxis with AZT for 1 to 4 weeks.
Previous reports show that the rate of pregnant women who received antiretroviral therapy
in GQ to prevent mother-to-child transmission (PMTCT) increased from 30.2% in 2012 to
78.6% in 2013. This is higher than in the general population which in 2013 increased 28.4% in
adults and 6.3% in children [1]. Surveillance of drug resistance to antiretroviral drugs is partic-
ularly important in the pregnant population as infection by drug-resistant virus has implica-
tions for both maternal treatment and neonatal prophylaxis.
The WHO recommends population-based surveys to detect whether the prevalence of resis-
tance in ART naive and ART-treated people is reaching alerting levels [3]. Updated resistance
data can guide clinicians towards first-antiretroviral regimen selection in drug-naive subjects
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or to optimization of second-lineART regimens in pretreated patients under virological failure.
However, despite its high and increasing HIV prevalence, the scale-up of ART in GQ, and the
close location to the epicenter of the HIV-1 pandemic, the country lacks systematic surveillance
studies to monitor drug resistance and to detect changes in HIV-1 molecular epidemiology.
HIV-1 genotypic resistance testing is routinely done in developed countries to identify drug
resistance mutations but it has not yet been implemented in GQ.
Identification of the circulating HIV-1 variants is important since some of them have clinical
relevance, affecting disease progression [4]. Furthermore, due to high genetic variability and
viral evolution, HIV presents variant-specific natural polymorphisms along the viral genome,
some of them in residues associated with drug resistance [5,6]. They can influence the genetic
barrier [7], the resistance pathways [8], the viral fitness [9], and the susceptibility to specific
antiretrovirals [10,11]. Also, some natural polymorphisms favor the emergence of variants fully
resistant to antiretrovirals [12], which not only affect drug-resistance interpretation when using
different algorithms and generate discrepant results [13], but also increase ART-failure risk in
some subtypes [14–16]. HIV-1 genetic variability can also lead to viral load (VL) underestima-
tion or to no HIV-1 RNA detection [17], thus affecting early molecular diagnosis and ART-
monitoring [17–20]. Since dried blood spots (DBS) are less infective, easier to collect, store, and
transport than whole blood or plasma and with comparable performance for monitoring HIV
infection in Public Health Programs [21], the WHO has recommended their use for improving
access to virological testing, including viral load and drug resistance monitoring [22].
For a better efficacy of PMTCT regimens, documenting the profile of drug resistance in
HIV-infected pregnant women is crucial for improving the maternal ART and prophylaxis in
infants. To date, only few studies have reported resistance data and information regarding the
HIV-1 subtypes and recombinants circulating in GQ. All the published data were obtained
from specimens collected from 1997 to 2011 [23–25], but no data have been reported about the
pregnant women collective. These previous studies revealed a complex epidemic in the country,
where the prevalent HIV-1 variant is CRF02_AG, as in the neighboring countries [26]. Thus,
the main objective of this study was to describe the presence of transmitted antiretroviral drug
resistance mutations (TDR) and ADR and the current circulating HIV-1 variants among HIV-
1 infected pregnant women participating in a PMTCT program at Hospital Regional of Bata
and Primary Health Care Centre María Rafols, in Bata, GQ during the 2012–2013 period.
Materials and Methods
Study population and sample collection
The PMTCT program is a national and centralized program previously established in 2008 in
GQ and centralized at two centers in Bata (Hospital Regional and Primary Health Care Center
Maria Rafols) and one in Malabo (Hospital Regional). For this study, DBS were collected from
all the 69 HIV-1 infected women following the PMTCT program during the 14 months study
period (November 2012 to December 2013) in the two centers from Bata. All of them gave
written informed consent to participate in this study, previously approved by human subjects
review committees at Hospital Regional of Bata (Bata, GQ) and Hospital Universitario de
Getafe (Madrid, Spain).
The samples were collected close to delivery by venipuncture and two drops of blood were
spotted into each dot on a Whatman™ 903 Protein Saver Card (Schleicher& Schuell, USA).
The women had a median age of 22 years (IQR 20–25). These dots, when saturated, are esti-
mated to hold about 70 μl of blood.DBS cards were dried separately on a drying-rackovernight
at room temperature in the hospital. Two cards (5 dots per card) were taken per patient, sealed
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in a zip-lock plastic bag with desiccant bags and stored at -20°C until their transport in dry ice
to the laboratory in Madrid, Spain, where the samples were stored at -80°C until further use.
HIV-1 sequencing for resistance testing and variant identification
RNA was extracted from DBS using the NucliSENS easyMAG automated platform (BioMèr-
ieux, Marcy l´Etoile, France), followed by an in-house RT-PCR and nested-PCR to amplify the
complete HIV-1 protease gene (codons 1–99) and partial reverse transcriptase gene (codons
1–335) as previously described [27]. PCR amplicons were purified using the illustra™ ExoProS-
tar™ (GE Healthcare Life Sciences, Little Chalfont, UK) and sequenced by Macrogen Inc.
(Gasan-dong, Geumchun-gu, Seoul, Korea).
For resistance testing, pol sequences (protease-PR and/or partial reverse transcriptase-RT)
from antiretroviral-naive pregnant women were used to identify the TDR and quantify its
prevalence following the WHO mutation list [28] and using the Calibrated Population Resis-
tance tool (http://cpr.stanford.edu). ADR was studied using pol sequences from antiretroviral-
exposed subjects considering substitutions following the 2015 International AIDS Society-USA
(IAS-USA) mutation list [29].
In those viruses carryingDRM, predicted susceptibility to each drug was evaluated using
Stanford’s HIVdb Algorithm (http://sierra2.stanford.edu/sierra/servlet/JSierra)in the available
PR and/or RT sequence. We classified predicted drug resistance in three categories depending
on mutation scores: low-level, intermediate, and high-level resistance according to Stanford’s
HIVdb Algorithm.
For HIV-1 subtype or CRF characterization we performed phylogenetic analyses (phy)
using the Phylip software after editing the generated pol sequences using SeqMan from the
DNAstar package v7.1.0 (Lasergene,USA). We aligned sequences including at least two repre-
sentative sequences of each 9 HIV group M subtypes and each 66 of the 79 circulating recombi-
nant forms (CRFs) available at Los Alamos HIV sequence database (http://www.hiv.lanl.gov/
content/sequence/HIV/CRFs/CRFs.html), as well as additional pol sequences from circulating
HIV-1 variants previously described in GQ [25]. The tree topology was obtained using the
Neighbour-Joining method. Alignment of DNA sequences was performed using the ClustalW
program. The pairwise distance matrix was estimated using the Kimura two-parameter model.
Bootstrap re-sampling (1000 data sets) of the multiple alignments was performed to test the
statistical robustness of the tree, considering only the nodes with a bootstrap value over 700
[30]. Sequences not identified as any known subtype or CRF by phy were considered unique
recombinant forms (URF).
Accession Numbers
PR and/or RT sequences from DRM and subtyping testing of the study population were sub-
mitted to GenBank (www.ncbi.nlm.nih.gov/genbank) with the following accession numbers:
KP890858-KP890927.
Viral load quantification
We used the VERSANT1 HIV-1 RNA 1.0 (kPCR) assay (Siemens Healthcare Diagnostics,
Tarrytown, USA) for HIV-1 plasmatic VL quantification from DBS. One spot was incubated
for 30 minutes at room temperature with gentle rotation in 2 mL of Siemens DBS-specific lysis
buffer including guanidine thiocyanate (not available for sale). Then, 1.1 mL of the supernatant
was processed for automated nucleic acid extraction. Amplification software and settings of the
kPCR assay were used without modification, as previously published [31]. As the haematocrit
percentage was unknown in each pregnant woman, we assumed a mean value of 31.7% [32] in
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order to estimate the corrected DBS VL result, as recently reported [31]. The limit of detection
of this assay is 894 HIV-1 RNA copies/mL (cp/mL) when using DBS [31].
Statistical analysis
All statistical analyses were conducted using SPSS 13.0. Prevalences were expressed in percent-
age. Significancewas set at p<0.05.
Results
The 69 HIV-1 infected pregnant women selected during the PMTCT program in two health
centers in Bata, GQ, during 2012–2013, had a median age of 22 years, all were infected by the
heterosexual route, and half of them were asymptomatic (50.7% with WHO clinical stage 1)
(Table 1). Among the 69 women, 12 (17.4%) were naive for the three drug classes at sampling
time, 55 (79.7%) were on TAR and in 2 (2.9%) cases the presence or absence of ART was not
reported in clinical reports. Among these 55 women, 21 had received monotherapy with AZT
and 34 cART as first regimen. We were able to amplify HIV-1 partial pol sequences from 38
(55.1%) of the 69 infected pregnant women under study.
Among the 38 women with available pol sequence (34 had available PR and 28 available
nearly complete RT sequences), 30 (78.9%) were under ART when samples were collected. The
remaining 8 (21.1%) women were ARV naive for the three drug families (Table 1). However,
when considering specific drug families, 8 of the 38 were naive for NRTI, 25 for NNRTI and 33
for PI. These naive women did not have ARV experience as they had not received previous
antiretroviral therapies or any form of antenatal care according to clinical reports in GQ.
Table 1. Epidemiological and virological features of the HIV-1 infected study population.
Features Study cohort With available PR and/or RT sequence
Number of HIV-1 infected women 69 38
Htsex transmission route 69 (100%) 38 (100%)
Clinical status (WHO)
I 35 (50.7%) 19 (50%)
II 2 (2.9%) 1 (2.6%)
III 1 (1.4%) 0
IV 0 0
Unknown 31 (44.9%) 18 (47.4%)
Vaginal delivery 55 (79.7%) 30 (78.9%)
HIV-1 transmission to newborns 2 (2.9%) 2 (5.3%)
ARV therapy
ARV naive for the three drug families 12 (17.4%) 8 (21.1%)
ARV exposed1 55 (79.7%) 30 (78.9%)
Unknown 2 (2.9%) 0
Carrying DRM - 8 (21.1%)
HIV-1 variants
Subtype B - 1 (2.6%)
Non-B subtypes - 37 (97.4%)
Recombinants - 29 (76.3%)
Htsex, heterosexual; WHO, World Health Organization; ARV, antiretroviral; DRM, drug resistance
mutations. Among the 38 patients with available pol sequence data, 34 had available PR and 28 available
RT sequences.
doi:10.1371/journal.pone.0165333.t001
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S1 Table lists the main clinical and virological features of the 69 women under study, including
age, type of delivery, viraemia, HIV-1 variant, ART experience prior to sampling time, and
DRM found in each drug family. Among the 69 women of the study cohort, 35 (50.7%) had
VLs>1,000 cp/ml (value considered as detectable viraemia according to WHO recommenda-
tions when using DBS), 13 (18.8%) had VLs<1,000 cp/ml and in 21 (30.4%) cases HIV-1 was
not detected. In 3 (8.6%) of the 35 patients with VLs>1,000 cp/mL it was not possible to
amplify the virus genome to obtain the sequence.
Considering only the 55 women under TAR at sampling time, 28 (50.9%) had VLs<1,000
cp/mL, and 27 (47.9%) had VLs>1,000 cp/mL. The high VL among 19 (76%) women under
TAR under ART and VL>1,000 without MDR could suggest suboptimal adherence or unade-
quate dosing, among others. Unfortunately, information related to adherence to ART was not
available in clinical reports.
Considering the 31 patients with no available sequence, 10 had VL<1,000 cp/mL, in 18
cases the virus was not detected and only 3 women had VL>1,000 cp/mL ranging 1,065–2,016
cp/mL. Although most (66.7%) of the 12 ARV-naive pregnant women presented detectable vir-
aemia as expected in the absence of ART, 3 (25%) of them showed VL<1000 cp/ml and 1 had
undetected vireamia (S1 Table). Among the 38 women with available pol sequence, 32 (84.2%)
had VL>1,000 cp/ml.
Fifteen (50%) of the ART-treated women had been exposed to nucleoside reverse transcrip-
tase inhibitors (NRTI), mainly to monotherapy with AZT. The other fifteen had received
cART as first regimen, based on triple therapy including two NRTI [emtricitabine (FTC), teno-
fovir (TDF), AZT or 3TC] and one non-NRTI [NNRTI; efavirenz (EFV) or NVP] or one prote-
ase inhibitor or (PI)-boosted Lopinavir (LPV/r). The ARV experience in each woman is shown
in S1 Table. Among the 30 ART-experienced pregnant women with available pol sequence, 25
(83.3%) presented VL>1,000cp/ml at sampling time (median: 2,405 cp/mL; range: 1,192–
178,025).
S2 Table shows all mutations found at viruses from the 38 women with available PR and/or
RT sequence. No HIVDR was observed in these 12 patients naive for the three drug families.
Considering drug families, no TDR was found in NRTI or NNRTI-naive women, but the TDR
rate for PI was 3.4% (1/29), since D30N change at PR was detected in a PI-naive woman carry-
ing a CRF02_AG recombinant. The ADR rate was 37.5% for NNRTI, 8.7% for NRTI and was
absent for PI among women exposed to the corresponding drug family (S2 Table). No case of
NNRTI+NRTI resistance was found. When considering the 25 patients on ART at sampling
time with VL>1,000 cp/ml and available sequence, 6 (24%) presented ADR. Table 2 shows the
drug resistance rate and the DRM found among the 9 pregnant women from GQ carrying
HIV-1 resistant variants. In the study cohort, none of the 9 women carrying resistance viruses
transmitted the infection to their newborns and only 2 cases of HIV transmission to newborns
occurred, representing a rate of HIV-1 transmission of 2.9% [33], lower than that reported in
previous years [34].
Regarding the circulating HIV-1 variants, we observed a complex HIV-1 molecular epide-
miology in infected pregnant women, in agreement with previous studies in patients from GQ
[25]. Most (97.4%) infections were caused by group M non-B variants, and were mainly
(78.9%) recombinants (Table 3). CRF02_AG caused slightly more than half (55.2%) of the
infections, followed by CRF22_A101 (10.5%), subtype C (10.5%), unique recombinant forms
(5.3%) and 2.6% of each sub-subtypes A3 and F2, subtypes B, D, and G, and recombinants
CRF06_cpx and CRF11_cpx. We found an increase of infections caused by recombinant vari-
ants with respect to that reported in previous studies in GQ during 1997–2011 preformed at
different sampling period and distinct HIV-infected collectives [23–25] (Table 3).
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Discussion
The WHO 2016 guidelines recommend providing lifelong ART to all HIV patients regardless
of CD4 cell count but the monitoring of drug resistant HIV-1 is still a challenge to control the
HIV/AIDS epidemic. It needs to be strengthened on a global scale, and pregnant women living
with HIV should be considered one of the key target population [35]. Treating all HIV-infected
pregnant and breastfeeding women serves three purposes: improving the mother’s health, pre-
venting mother-to-child transmission of HIV, and preventing the viral transmission from the
mother to a sexual partner [36]. The possible harm of offering lifelong ART includes the poten-
tial for cumulative drug toxicity and the possibility of poor adherence with long-term use, lead-
ing to the development of drug resistance, which should be periodicallymonitored.
The identification of drug resistance mutations is crucial to publish first and rescue-line
ART guidelines at country level, as previously reported [35,37]. During the last years, different
rates of TDR or ADR to reverse transcriptase inhibitors have been reported in pregnant
women from some countries in Latin America [38–41], the Caribbean [42], and Sub-Saharan
Africa [43–51]. In GQ ART was scaled up in 2005. In 2012 National guidelines for the PMTCT
program in GQ recommended prophylaxis with AZT or cART in all HIV-infected pregnant
women depending on their CD4 count and WHO clinical stage (WHO Option A) [2]. How-
ever, despite the scaling up of ART in the country (74% in 2014) (http://www.unaids.org/en/
resources/presscentre/featurestories/2015/november/20151127_equatorialguinea) GQ lacks
systematic surveillance studies for monitoring drug resistance in the general population,
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55 Monotherapy AZT - - ND CRF02_AG D30N* NA NA NFV - -
39 Monotherapy AZT - - 5.3 CRF02_AG - M41L - - - AZT, d4T,
DDI










- - V106I - - -
20 cART TDF, FTC EFV - 2.9 Subtype C NA - V179D,
G190A
NVP EFV ETR, RPV
15 cART TDF, FTC EFV - 5.2 CRF02_AG - - E138A - - ETR, RPV
59 naive none none none 2.9 CRF02_AG - - V90I* - - -
51 Monotherapy AZT - - 4.5 CRF02_AG - - V90I* - - -
27 cART AZT, 3TC - LPV/
r
4.4 CRF02_AG - - V90I* - - -
ART, antiretroviral therapy; ARV, antiretroviral drug; DRM, drug resistance mutation according to IAS-USA 2015; NRTI, nucleoside reverse transcriptase
inhibitors: AZT, zidovudine; d4T, stavudine; DDI, didanosine; ABC, abacavir; FTC, emtricitabine; 3TC, lamivudine; NNRTI, non-nucleoside reverse
transcriptase inhibitors: NVP, nevirapine; EFV, efavirenz; ETR, etravirine; RPV, rilpivirine; PI, protease inhibitors: NFV, nelfinavir; cART, highly active
antiretroviral therapy; NA, data not available due to unsuccessful PCR- amplification in that genome region; ND, not detected (<894 cp/mL according to
Alvarez et al., 2014 [31]); Dash, no mutation or no predicted potential resistance found. Viral load in log RNA-HIV-1 copies/mL using Siemens VERSANT
HIV-1 RNA 1.0 kPCR assay. With asterisk, mutations considered as transmitted drug resistant. All women were receiving those antiretrovirals at genotyping
time.
* V90I was found in women naïve for NNRTI.
1 According to Stanford’s HIVdb Algorithm (http://sierra2.stanford.edu/sierra/servlet/JSierra).
doi:10.1371/journal.pone.0165333.t002
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including HIV-1 infected pregnant women, which can have an impact on the HIV vertical
transmission of resistant viruses.
According to the last National Report in GQ, during 2013 a total of 28.2% (10,384/36,800)
of pregnant women in the country knew her positive or negative HIV status [1]. Since HIV-
prevalence among pregnant women was 10.1% in the same year in GQ, it should represent
around 1,000 HIV-infected pregnant women in 2013 [1]. Thus, during the study period, our
study population would represent around 7% (69/1,000) of infected pregnant women in the
country and 100% of HIV-infected women under the national PMTCT program in Bata, the
second biggest city of GQ located in the continental area, with around a quarter of the nearly 1
million inhabitants living in the country [52].
In low resource countries the margin of long-term ARV treatment success is narrow because
NNRTI-based regimens have a low genetic barrier to resistance. In fact, ART failure with a
fixed-doseNRTI/NNRTI combination occurs in 10% to 30% of patients per year [53–55], and
most patients with virological failure acquire NRTI and/or NNRTI resistance [55–57]. The first-
line therapy in GQ includes two NRTI and one NNRTI leading to a good response with the
proper adherence. However, if the woman has previously received NNRTIs in a non-continuous
way, there is a risk of selection of resistance to NNRTIs. Among the studied pretreated pregnant
women in GQ, we observeda high rate of NNRTI resistance present in more than a third of
Table 3. HIV-1 group M variants reported in patients from GQ during 1997–2013.
HIV-1 M variant Yebra et al., 20131 This study
Sampling year 1997–2011 2012–2013
HIV-1 infected collective General population Pregnant women
Number of patients 278 38
(p-value)
Sequenced gene pol pol
Subtyping method phy phy
Pure subtypes 122 (43.9%) 9 (23.7%) <0.05
A 38 (13.7%) 1 A3 (2.6%) NS
B 20 (7.2%) 1 (2.6%) NS
C 16 (5.7%) 4 (10.5%) NS
D 14 (5.0%) 1 (2.6%) NS
F 11 (4.0%) 1 F2 (2.6%) NS
G 15 (5.4%) 1 (2.6%) NS
H 8 (2.9%) 0 NS
Recombinants 156 (56.1%) 29 (76.3%) <0.05
CRF02_AG 133 (47.8%) 21 (55.2%) NS
CRF06_cpx 4 (1.4%) 1 (2.6%) NS
CRF09_cpx 1 (0.4%) 0 NS
CRF11_cpx 7 (2.5%) 1 (2.6%) NS
CRF13_cpx 3 (1.1%) 0 NS
CRF18_cpx 1 (0.4%) 0 NS
CRF22_01A1 3 (1.1%) 4 (10.5%) <0.05
URF 4 (1.4%) 2 (5.3%) NS
GQ, Equatorial Guinea; CRF, circulating recombinant form; URF, unique recombinant form. Phy, phylogenetic analysis of HIV-1 sequences (pol or env).
NS, not significant (p>0.05).
1According to Yebra et al., 2013 [25]. That study analyzes pol sequences from 195 HIV-infected Equatoguinean subjects attending Spanish clinics during
1997–2011 and 83 GenBank sequences sampled in GQ in 1997 and 2008 from military personnel in Malabo and general infected population in the country.
doi:10.1371/journal.pone.0165333.t003
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women with available sequence, probably explained by the use of NVP and EFV as part of most
PMTCT regimens in our study cohort. The selection of resistance to NNRTIs in cART could be
favored by the low genetic barrier of NNRTIs and by inadequate adherence [58,59].
Regarding NRTI, DRM selection to AZT in pregnant women with low HIV-1 viraemia and
receiving monotherapy with AZT during pregnancy is uncommon [60], as seen in our study.
Since DRM to PI were absent in the treated population, PI could be a good candidate to be
included in rescue regimens in GQ.
We observed a low prevalence of TDR in the population, with only one naive woman carry-
ing resistant virusesmaybe transmitted by her sexual partner. However, TDR might be more
prevalent given the ART interruptions and other extenuating factors that negatively affect
adherence in GQ and other resource poor nations [61]. This TDR could be selected (or extin-
guished) by future antiretroviral exposure in those women.
Our data reveal that 17.4% of the women participating in this study were naive for NRTI,
NNRTI and PI, despite being included in a PMTCT program. Moreover, half of the 55 women
on ART presented detectable viraemia at sampling time, suggesting low adherence to ART.
The high VL observed at sampling time in the absence of DRM after ARV exposure among
some treated women is also suggestive of an inappropriate adherence to treatment. Poor adher-
ence to ART in pregnant women is a major problem in Sub-Saharan Africa, since it is a predic-
tor of virological failure, emergence of resistant viruses, disease progression and death [35].
Long-standing health-system issues (such as staffing and service accessibility), educational fac-
tors (poor knowledge of HIV/ART/vertical transmission and a low maternal educational level)
and community-level factors (particularly stigma, psychosocial distress, fear of disclosure and
lack of partner or community support) still make the access to ART very difficult and could
explain the lack of uptake of antiretroviral drugs in these women, as previously reported [61].
Our study encourages the importance of reinforcing the PMTCT program in Bata so that all of
the participants receive ART before the delivery, avoiding losses in the cascade of care from
HIV diagnosis to the start of ART.
Our results provide the most recent data regarding the HIV-1 molecular epidemiology in
GQ. We confirmed the predominance of HIV-1 recombinant variants, observingCRF02_AG
in nearly 55% of infections. We also noticed an increase of infections caused by URF compared
to previous years. HIV-1 recombination is a powerful evolutionary force that occurs ten-fold
more frequently than punctual mutations and produces and maintains further variability by
shuffling and combining viral genetic material. The continuous evolution and diversification of
HIV will bring new challenges for its prevention, treatment and virological monitoring using
molecular tools [62–65]. As we did not study the complete HIV genome, the rate of recombi-
nants could have been even higher if more viral regions had been assessed.
This study presents some limitations. Data on number of pregnancies or previously infected/
exposed children from the 69 women were not available in clinical reports provided by GQ cli-
nicians, but it is unlikely that these women were exposed to ART before participating in the
PMTCT program. As most of the included 69 women were under ART at sampling leading to
low VL, we were able to obtain resistance data from 38 women, representing 55.1% of the whole
cohort, a high rate compared to other reports performed on treated pregnant women [38,48,49].
Following WHO recommendations for resistance testing in limited resources settings, we used
DBS for sample collection (only four drops of eluted dried blood) to obtain the HIV sequence,
whereas all resistance studies in pregnant women apart from one in Tanzania [43], were carried
out on higher volumes of plasma or whole blood [38–42,44–51]. Although DBS samples were
collected during 2012 and 2013, the drug resistance and molecular epidemiologydata provided
are the first to be reported in the pregnant women collective in GQ, giving valuable information
for clinicians and for National Health authorities in the country.
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The present data have relevant importance since, according to UNAIDS, correct HIV-1
monitoring and ART in Bata and Malabo, the two main cities in the country, would signifi-
cantly reduce HIV infection in the country (http://www.unaids.org/es/resources/presscentre/
featurestories/2015/november/20151127_equatorialguinea). Since the Bata population presents
a lower HIV rate among pregnant women than the population of the insular region of GQ [1]
and that the urban population in Bata presents large differences from the rural areas in GQ in
terms of fertility rates and access to the current PTCTM services, resistance studies should be
reinforced in this key collective of HIV-1 pregnant women in Equatorial Guinea.
In conclusion, the low presence of DRM to PI among naive women and the high DRM rate
to retrotranscriptase inhibitors (mainly NNRTIs) observed among pretreated women, rein-
force the importance of systematic DRM monitoring in pregnant women in GQ. This could
reduce HIV-1 resistance transmission to newborns or to sexual partners, optimize first and sec-
ond-line ART regimens when DRM are present, and preserve future ART options in infected
patients carrying resistant viruses in the country. Continuous adherence counselling and peri-
odic monitoring of the virological response is crucial for a successful implementation of ART
in pregnant women during PMTCT programs.
Supporting Information
S1 Table. Clinical features, HIV-1 variant, and viral load of the 69 pregnant women under
study in Equatorial Guinea. ID, identification;WHO, World Health Organization; PMTCT
ART, antirretroviral therapy recieved during the prevention of mother-to-child transmission
program; ART, antiretroviral; cp/ml HIV RNA copies/milliliter;DRM, drug resistance muta-
tion; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse tran-
scriptase inhibitor; PI, protease inhibitor; cART, combined antiretroviral therapy; ATZ,
zidovudine; ND, not detected by kPCR assay. No, patients under ART including NRTI,
NNRTI and PI. Patients highlighted in grey had detectable viral load (>1,000 cp/ml).
(DOC)
S2 Table. Genotyping results among the 38 HIV-1 infected pregnant women with available
PR and/or RT sequences.HIVDR, viral resistancemutations to antiretrovirals. In blue,
changes at RT residues involved at resistance but not included at IAS2015 and Bennett list.
With asterisk, changes present in virus collected from naive pregnant women absent in Bennett




Data curation: LP AV.
Formal analysis: P. Alvarez AH.
Funding acquisition: LP AH.
Investigation: P. Alvarez LP AV AH.
Methodology:P. Alvarez CFM LM.
Project administration: LP AH.
Resources: LP JO P. Avedillo AV PR.
HIV-1 Epidemiology in Pregnant Women from GQ




Writing – original draft: P. Alvarez AH.
Writing – review& editing: LP AB JTR AH.
References
1. República de Guinea Ecuatorial. Informe Nacional sobre los progresos realizados en la lucha contra el
VIH/SIDA en Guinea Ecuatorial. Indicadores básicos para el seguimiento de la declaración polı́tica
sobre el VIH/SIDA. Programa Nacional de Lucha contra el SIDA. 2014. Available: http://www.unaids.
org/sites/default/files/country/documents/GNQ_narrative_report_2014.pdf. Accessed 2016 Sep 26.
2. Ministerio de Sanidad y Bienestar Social de Guinea Ecuatorial. Protocolo de diagnostico y seguimiento
por laboratorio del VIH/SIDA en Guinea Ecuatorial. 1st Ed. Malabo: MINSABS2009. 2009.
3. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of
transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008; 13:
25–36. PMID: 18575189
4. Pant Pai N, Shivkumar S, Cajas JM. Does genetic diversity of HIV-1 non-B subtypes differentially
impact disease progression in treatment-naive HIV-1-infected individuals? A systematic review of evi-
dence: 1996–2010. J Acquir Immune Defic Syndr. 2012; 59: 382–388. doi: 10.1097/QAI.
0b013e31824a0628 PMID: 22269800
5. Martinez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA. Role of genetic diversity amongst HIV-1 non-
B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev.
2008; 10: 212–223. PMID: 19092977
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